Efficacy Of Pegylated Interferon And Ribavirin Treatment In Coinfected HIV HCV Patients

1. Anderson, K.B., Guest, J.L. & Rimland, D. (2004). Hepatitis C virus coinfection increases mortality in HIV-infected patients in the highly active antiretroviral therapy era: data from the HIV Atlanta VA Cohort Study. Clin Infect Dis. 39(10), 1507-1513. doi: 10.1086/425360Search in Google Scholar

2. Alvarez, D., Dieterich, D.T., Brau, N., Moorehead, L., Ball, L. & Sulkowski, M.S. (2006). Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons. J Viral Hepat. 13(10), 683-689. doi: 10.1111/j.1365-2893.2006.00749.x.Search in Google Scholar

3. Bica, I., McGovern, B., Dhar, R., Stone, D., McGowan, K., Scheib, R. & Snydman, D.R. (2001). Increasing mortality due to endstage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis. 32(3), 492-497. doi: 10.1086/318501.Search in Google Scholar

4. Cohen, M.H., French, A.L., Benning, L., Kovacs, A., Anastos, K., Young, M., Minkoff, H. & Hessol, N.A. (2002). Causes of death among women with human immunodeficiency virus infection in the era of combination antiretroviral therapy. Am J Med. 113(2), 91-98.10.1016/S0002-9343(02)01169-5Search in Google Scholar

5. Fleischer, R., Boxwell, D. & Sherman, K.E. (2004). Nucleoside analogues and mitochondrial toxicity. Clin Infect Dis. 38(8), e79-80. doi: 10.1086/383151.Search in Google Scholar

6. Graham, C.S., Baden, L.R., Yu, E., Mrus, J.M., Carnie, J., Heeren, T. & Koziel, M.J. (2001). Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis. 33(4), 562-569. doi: 10.1086/321909.Search in Google Scholar

7. Jacobson, I.M., McHutchison, J.G., Dusheiko, G., Di Bisceglie, A.M., Reddy, K.R., Bzowej, N.H., Marcellin, P., Muir, A.J., Ferenci, P., Flisiak, R., George, J., Rizzetto, M., Shouval, D., Sola, R., Terg, R.A., Yoshida, E.M., Adda, N., Bengtsson, L., Sankoh, A.J., Kieffer, T.L., George, S., Kauffman, R.S., Zeuzem, S. & Team, A.S. (2011). Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med. 364(25), 2405-2416. doi: 10.1056/ NEJMoa1012912Search in Google Scholar

8. Laufer, N., Laguno, M., Perez, I., Cifuentes, C., Murillas, J., Vidal, F., Bonet, L., Veloso, S., Gatell, J.M. & Mallolas, J. (2008). Abacavir does not influence the rate of virological response in HIVHCV- coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. Antivir Ther. 13(7), 953-957.10.1177/135965350801300709Search in Google Scholar

9. Martin-Carbonero, L., Soriano, V., Valencia, E., Garcia-Samaniego, J., Lopez, M. & Gonzalez- Lahoz, J. (2001). Increasing impact of chronic viral hepatitis on hospital admissions and mortality among HIV-infected patients. AIDS Res Hum Retroviruses. 17(16), 1467-1471. doi: 10.1089/08892220152644160.Search in Google Scholar

10. Mira, J.A., Lopez-Cortes, L.F., Barreiro, P., Tural, C., Torres-Tortosa, M., de Los Santos Gil, I., Martin-Rico, P., Rios-Villegas, M.J., Hernandez-Burruezo, J.J., Merino, D., Lopez- Ruz, M.A., Rivero, A., Munoz, L., Gonzalez- Serrano, M., Collado, A., Macias, J., Viciana, P., Soriano, V. & Pineda, J.A. (2008). Efficacy of pegylated interferon plus ribavirin treatment in HIV/hepatitis C virus co-infected patients receiving abacavir plus lamivudine or tenofovir plus either lamivudine or emtricitabine as nucleoside analogue backbone. J Antimicrob Chemother. 62(6), 1365-1373. doi: 10.1093/jac/ dkn420Search in Google Scholar

11. Poordad, F., McCone, J., Jr., Bacon, B.R., Bruno, S., Manns, M.P., Sulkowski, M.S., Jacobson, I.M., Reddy, K.R., Goodman, Z.D., Boparai, N., DiNubile, M.J., Sniukiene, V., Brass, C.A., Albrecht, J.K., Bronowicki, J.P. & Investigators, S.-. (2011). Boceprevir for untreated chronic HCV genotype 1 infection. N Engl J Med. 364(13), 1195-1206. doi: 10.1056/NEJMoa1010494.Search in Google Scholar

12. Rodriguez-Torres, M., Slim, J., Bhatti, L., Sterling, R., Sulkowski, M., Hassanein, T., Serrao, R., Sola, R., Bertasso, A., Passe & Stancic, S. (2012). Peginterferon alfa-2a plus ribavirin for HIV-HCV genotype 1 coinfected patients: a randomized international trial. HIV Clin Trials. 13(3), 142-152. doi: 10.1310/hct1303-142.Search in Google Scholar

13. Serrano-Villar, S., Quereda, C., Moreno, A., Perez-Elias, M.J., Casado, J.L., Royuela, A., Dronda, F., Navas, E., Hermida, J.M. & Moreno, S. (2013). Neutropenia during therapy with peginterferon and ribavirin in HIV-infected subjects with chronic hepatitis C and the risk of infections. Clin Infect Dis. 57(3), 458-464. doi: 10.1093/cid/cit221Search in Google Scholar

14. Tuma, P., Jarrin, I., Del Amo, J., Vispo, E., Medrano, J., Martin-Carbonero, L., Labarga, P., Barreiro, P. & Soriano, V. (2010). Survival of HIV-infected patients with compensated liver cirrhosis. AIDS. 24(5), 745-753. doi: 10.1097/ QAD.0b013e3283366602.Search in Google Scholar

15. Vispo, E., Barreiro, P., Pineda, J.A., Mira, J.A., Maida, I., Martin-Carbonero, L., Rodriguez- Novoa, S., Santos, I., Lopez-Cortes, L.F., Merino, D., Rivero, A. & Soriano, V. (2008). Low response to pegylated interferon plus ribavirin in HIV-infected patients with chronic hepatitis C treated with abacavir. Antivir Ther. 13(3), 429-437.10.1177/135965350801300303Search in Google Scholar